Biotech sector eyes key clinical trial readouts in H2 2026 across cancer, Alzheimer’s and autoimmune diseases

The first half of 2026 saw a surge in biotech activity, with record‑high deal flow, several large IPOs and a regulatory environment that appears to be stabilising after a period of uncertainty.

Analysts note that upcoming data from trials targeting lung cancer, Alzheimer’s disease and a range of autoimmune conditions could further energise the market if the results are positive.

The article highlights ten specific studies slated for readout in the second half of the year, spanning indications such as pancreatic cancer, hepatitis B and obesity, among others, and suggests these will be closely watched by investors and clinicians alike.